Every Form 4 that Inogen Inc (INGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INGN filings page.
Inogen Inc (INGN) reported that Mary E. Wright, its Vice President and Chief Accounting Officer, acquired 1,500 shares of Inogen common stock on September 1, 2026. The shares were acquired through the company’s 2014 Employee Stock Purchase Plan, bringing her directly held stake to 20,629 shares.
Inogen Inc (INGN) reported that executive vice president Kevin P. Smith completed multiple equity transactions on September 1, 2026, in connection with restricted stock units and the employee stock purchase plan, reported as made under a Rule 10b5-1 trading plan. An award of 18,136 restricted stock units was exercised into an equal number of common shares, with 8,671 of those shares withheld to satisfy tax withholding liability and 1,500 additional shares acquired through the 2014 Employee Stock Purchase Plan at $5.33 per share. Following the vesting event, 18,135 restricted stock units remain outstanding and subject to future vesting.
Inogen Inc (INGN) reports that CEO, President, and director Kevin Raymond Merrill Smith acquired 1,500 shares of common stock on September 1, 2026 through the company’s 2014 Employee Stock Purchase Plan at $5.33 per share. The filing shows he now directly owns 134,962 shares, with the transaction made under a Rule 10b5-1 trading plan.
Reding Andrew P. reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc executive Andrew P. Reding, EVP and COO, received a grant of 130,000 restricted stock units. Each unit represents the right to receive one share of Inogen common stock. One-third of the units will vest one year from September 1, 2026, with the remaining two thirds vesting in equal annual installments on the same date in subsequent years, subject to his continued service.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief HR Officer, sold 10,938 shares of common stock in an open-market transaction on July 1, 2026 at a weighted average price of $6.5959 per share under a pre-arranged Rule 10b5-1 trading plan.
After this sale, she directly holds 5,039 shares of Inogen common stock.
Sahney Mira Kirti reported acquisition or exercise transactions in this Form 4 filing.
Inogen director Mira Kirti Sahney received an equity grant of 28,081 shares of Common Stock through a restricted stock unit award. The grant date was June 5, 2026.
The award vests on the earlier of the one-year anniversary of the grant or the day prior to the next Annual Meeting of stockholders, subject to her continued service. After this grant, she directly holds 67,805 shares of Inogen stock. This is compensation-related, not an open-market purchase.
Jamali Vafa reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Jamali Vafa received a grant of 28,081 shares of common stock as a restricted stock unit award on June 5, 2026, at no cash cost. Following the award, Vafa directly holds 43,081 shares. The restricted stock units vest on the earlier of one year after grant or the day before the next annual stockholder meeting, subject to continued service.
Inogen Inc director Glenn S. Boehnlein received an equity grant of 28,081 shares of Common Stock on June 5, 2026, at no cash cost, reported as acquired pursuant to a restricted stock unit award. The award will vest on the earlier of the one-year anniversary of the grant date or the day before Inogen’s next Annual Meeting of stockholders, subject to his continued service. Following this grant, Boehnlein directly holds 104,966 shares of Inogen common stock.
Rider Heather D. reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Heather D. Rider received an equity grant in the form of restricted stock units. She was awarded 28,081 shares of common stock at no purchase price, bringing her directly held stake to 116,282 shares. According to the award terms, these restricted stock units will vest on the earlier of the one-year anniversary of the grant date or the day before Inogen’s next Annual Meeting of stockholders, as long as she continues in service with the company.
Mora Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Elizabeth Mora received 28,081 shares of common stock as a restricted stock unit award. These RSUs were granted at no cash cost and increase her direct holdings to 107,261 shares. The award will vest after about one year, subject to her continued service.
Ladone Mary Kay reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Mary Kay Ladone received a grant of 28,081 shares of common stock through a restricted stock unit award. After this compensation grant, she directly holds 104,966 shares. The RSUs will vest on the earlier of one year from grant or the day before the next annual stockholders meeting, assuming she continues in service.
King Kevin M reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Kevin M. King received a grant of 28,081 shares of common stock through a restricted stock unit award. The award was made at no cash cost per share and is a form of equity compensation rather than an open-market purchase.
Following this grant, King directly holds 104,966 shares of Inogen common stock. According to the award terms, the restricted stock units will vest if he continues serving the company until the earlier of one year from the grant date or the day before the next annual stockholder meeting.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief Human Resources Officer, reported an open-market sale of 10,770 shares of common stock on May 29, 2026. The shares were sold at a weighted average price of $6.5286, within a price range of $6.41 to $6.62.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following this sale, she directly holds 15,977 shares of Inogen common stock.
Richardson Jason Andrew reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc granted Executive Vice President, Chief Financial Officer and Treasurer Jason Andrew Richardson 100,000 restricted stock units on April 6, 2026. Each unit represents a contingent right to receive one share of Inogen common stock.
The award vests over three years, with one-third of the units vesting one year after June 1, 2026, and the remaining two-thirds vesting in equal annual installments on the same calendar date, subject to his continued service.
Inogen Inc executive Mary E. Wright, the VP and Chief Accounting Officer, reported several equity compensation transactions. On March 1, 2026, multiple restricted stock unit tranches, including 1,755, 2,750 and 3,001 units, were exercised or converted into common stock at no cash cost. She also received common stock grants of 1,500 and 1,351 shares, while 675, 520, 1,058 and 1,155 shares of common stock at $6.10 were withheld to cover tax liabilities on the vesting awards. A separate grant of 8,000 restricted stock units was awarded on February 27, 2026, with vesting over several years subject to continued service.
Inogen Inc executive Jennifer M. Yi Boyer reported multiple equity award events. On February 27, 2026, she received a grant of 32,500 restricted stock units, each representing one share of common stock. These units vest in three equal annual installments starting March 1, 2027, subject to continued service.
On March 1, 2026, restricted stock units previously granted fully vested or were earned based on 2025 financial performance, and were converted into common shares. In connection with these vestings, blocks of shares were withheld at $6.10 per share to cover tax liabilities. After these transactions, she directly owned 26,747 shares of Inogen common stock.
Inogen’s Chief Commercial Officer Gregoire Ramade reported equity compensation activity involving restricted stock units and common shares. On March 1, 2026, 13,005 restricted stock units were exercised into 13,005 shares of common stock, and 6,022 shares were withheld at $6.10 per share to cover tax liabilities linked to a vesting award.
On February 27, 2026, Ramade received a new grant of 20,000 restricted stock units, each representing one share of Inogen common stock. One-third of this grant is scheduled to vest on March 1, 2027, with the remaining units vesting in equal annual installments on the same date in subsequent years, subject to continued service.
Inogen Inc executive Kevin P. Smith reported multiple equity compensation transactions. On February 27, 2026, he received a grant of 35,000 restricted stock units (RSUs), each representing the right to receive one share of Inogen common stock, subject to multi-year vesting based on continued service.
On March 1, 2026, 14,005 RSUs were exercised into common stock at no cost, and he was also awarded 1,500 shares of common stock at $6.10 per share. To cover tax withholding related to vested RSUs, 6,276 shares of common stock were disposed of at $6.10 per share. After these transactions, he directly held 22,007 shares of common stock and a remaining RSU balance as reported.
Inogen Inc EVP, CFO & Treasurer Michael J. Bourque reported multiple equity transactions. He acquired common stock through the vesting and exercise of restricted stock units on March 1, 2026, along with additional stock awards, and had shares withheld to satisfy tax obligations.
Several restricted stock unit awards converted into common stock at a stated price of $6.10 per share for tax purposes, with disposals labeled as tax-withholding transactions rather than open-market sales. After these transactions, he directly held 94,596 shares of Inogen common stock and 39,000 restricted stock units, each unit representing a contingent right to one share.
Inogen Inc CEO and President Kevin Raymond Merrill Smith reported multiple equity award transactions. On February 27, 2026, he received a grant of 90,000 restricted stock units, each representing a contingent right to one Inogen common share. Subject to continued service, one-third vests on March 1, 2027, with additional one-third portions vesting annually on the same date in subsequent years.
On March 1, 2026, performance-based and time-based restricted stock units vested, leading to share acquisitions and related tax-withholding dispositions. Vested awards included 28,334 and 30,012 shares from restricted stock units earned for 2025 financial performance, plus common stock awards of 685 and 32,725 shares. To cover tax liabilities on these vestings, the company withheld 16,374, 13,700, and 14,511 shares of common stock.
Inogen Inc's Chief Commercial Officer reports stock transactions linked to vesting restricted stock units. On December 1, 2025, the officer acquired 31,566 shares of common stock at an exercise price of $0 when a portion of a time-based restricted stock award vested. On the same day, 12,943 shares were withheld and disposed of at $6.95 per share to cover tax withholding obligations.
After these transactions, the officer directly owned 37,246 shares of Inogen common stock and held 31,565 restricted stock units. Each restricted stock unit represents the right to receive one share of Inogen common stock, with one-third of the units vesting on each anniversary of the December 1, 2023 vesting commencement date, subject to continued service.
Inogen Inc. disclosed an insider equity transaction involving its CEO and President, who also serves as a director. On December 1, 2025, a portion of a time-based restricted stock unit award vested, resulting in the acquisition of 28,334 shares of common stock at an exercise price of $0. To satisfy tax withholding obligations related to this vesting, 13,817 shares were withheld at a price of $6.95 per share. Following these transactions, the reporting person held 86,291 shares of Inogen common stock directly and 28,333 restricted stock units, which represent a contingent right to receive the same number of shares as they vest over time under the award’s vesting schedule.